Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Carré, M, Porcher, R, Finke, J, Ehninger, G, Koster, L, Beelen, D, Ganser, A, Volin, L, Lozano, S, Friis, L, Michallet, M, Tischer, J, Olavarria, E, Cascon, MJP, Iacobelli, S, Koc, Y, Jindra, P, Arat, M, de Witte, T, Yakoub Agha, I, Kröger, N & Robin, M 2020, 'Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation', Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol. 26, no. 3, pp. 451-457. https://doi.org/10.1016/j.bbmt.2019.10.015

APA

CBE

MLA

Vancouver

Author

Carré, Martin ; Porcher, Raphaël ; Finke, Jürgen ; Ehninger, Gerhard ; Koster, Linda ; Beelen, Dietrich ; Ganser, Arnold ; Volin, Liisa ; Lozano, Sara ; Friis, Lone ; Michallet, Mauricette ; Tischer, Johanna ; Olavarria, Eduardo ; Cascon, Maria Jesús Pascual ; Iacobelli, Simona ; Koc, Yener ; Jindra, Pavel ; Arat, Mutlu ; de Witte, Theo ; Yakoub Agha, Ibrahim ; Kröger, Nicolaus ; Robin, Marie. / Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant : A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 ; Vol. 26, No. 3. pp. 451-457.

Bibtex

@article{84fcbb06c3eb476397f161eafd924155,
title = "Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P< .0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.",
keywords = "Age, Comorbidities, Myelodysplastic syndromes, Nonrelapse mortality, Transplantation",
author = "Martin Carr{\'e} and Rapha{\"e}l Porcher and J{\"u}rgen Finke and Gerhard Ehninger and Linda Koster and Dietrich Beelen and Arnold Ganser and Liisa Volin and Sara Lozano and Lone Friis and Mauricette Michallet and Johanna Tischer and Eduardo Olavarria and Cascon, {Maria Jes{\'u}s Pascual} and Simona Iacobelli and Yener Koc and Pavel Jindra and Mutlu Arat and {de Witte}, Theo and {Yakoub Agha}, Ibrahim and Nicolaus Kr{\"o}ger and Marie Robin",
note = "Copyright {\textcopyright} 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = mar,
doi = "10.1016/j.bbmt.2019.10.015",
language = "English",
volume = "26",
pages = "451--457",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc",
number = "3",

}

RIS

TY - JOUR

T1 - Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant

T2 - A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

AU - Carré, Martin

AU - Porcher, Raphaël

AU - Finke, Jürgen

AU - Ehninger, Gerhard

AU - Koster, Linda

AU - Beelen, Dietrich

AU - Ganser, Arnold

AU - Volin, Liisa

AU - Lozano, Sara

AU - Friis, Lone

AU - Michallet, Mauricette

AU - Tischer, Johanna

AU - Olavarria, Eduardo

AU - Cascon, Maria Jesús Pascual

AU - Iacobelli, Simona

AU - Koc, Yener

AU - Jindra, Pavel

AU - Arat, Mutlu

AU - de Witte, Theo

AU - Yakoub Agha, Ibrahim

AU - Kröger, Nicolaus

AU - Robin, Marie

N1 - Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

PY - 2020/3

Y1 - 2020/3

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P< .0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P< .0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.

KW - Age

KW - Comorbidities

KW - Myelodysplastic syndromes

KW - Nonrelapse mortality

KW - Transplantation

U2 - 10.1016/j.bbmt.2019.10.015

DO - 10.1016/j.bbmt.2019.10.015

M3 - Journal article

C2 - 31647984

VL - 26

SP - 451

EP - 457

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -

ID: 59180415